FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.
Hosted on MSN1d
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...
BioPharma Dive1d
FDA clears use of Ozempic to protect kidney health
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
BioSpace1d
With Wegovy, Ozempic on the Line, Novo Asks Court to Speed Up IRA Complaint
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
Healio1d
‘We applaud CMS’: Two more rheumatology drugs bound for Medicare price negotiation
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...